Sales and distribution affiliate of Celltrion Group, marketing generic and branded pharmaceuticals in the Korean market.
Sales and distribution affiliate of Celltrion Group, marketing generic and branded pharmaceuticals in the Korean market.
Moat: none (distribution). Domestic sales arm within Celltrion Group; limited differentiation versus other generics distributors.
Headquarters: Cheongju, South Korea
Size Celltrion Pharm (068760.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.33B, the 195th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩40,250 on 18 Nov 2026.
Performance Over six months the shares fell 23.3%, against -17.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +7.6%); the operating margin is 11.6% (peer median 0.8%).
Valuation It trades at 3.0× enterprise value to sales against a peer median of 4.7× (7th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.0 points above its cost of capital (6.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩602B | ₩536B | ₩478B | ₩389B | ₩386B |
| Revenue growth | — | +12% | +23% | +1% | — |
| Gross profit | ₩186B | ₩161B | ₩118B | ₩117B | ₩112B |
| EBITDA | ₩93.8B | ₩78.4B | ₩57.3B | ₩55.7B | ₩55.6B |
| Net income | ₩49.1B | ₩38.8B | ₩22.0B | ₩21.3B | ₩26.0B |
| Free cash flow | ₩38.0B | ₩66.6B | ₩45.9B | -₩3.14B | -₩13.1B |
| Capital expenditure | ₩17.0B | ₩17.9B | ₩5.98B | ₩6.90B | ₩6.29B |
| Total debt | ₩160B | ₩161B | ₩172B | ₩163B | ₩161B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Celltrion Pharm 068760.KS | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% |
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 9.0× | 10.6% |
| Yuhan 000100.KS | $4.11B | -10% | +8% | 6% | 2.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 068760.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | -4.3% | 5th highest of 20 |
| 6-month return | -23.3% | -17.3% | 8th lowest of 20 |
| Distance from 52-week high | -48.6% | -38.9% | 6th lowest of 20 |
| Revenue growth (TTM) | +16.2% | +7.6% | 5th highest of 16 |
| Operating margin | 11.6% | 0.8% | 6th highest of 16 |
| EV / Sales | 3.0× | 4.7× | 7th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 2.5% | 2nd most demanding of 8 |
| Growth delivered (Del g) | +18.1% | +15.5% | 4th highest of 8 |
| Hurdle (Req g minus delivered) | -7.9 pp | -14.1 pp | 3rd most demanding of 8 |
| ROIC minus cost of capital | +4.0 pp | -3.3 pp | 4th highest of 16 |
| EV / EBITDA | 19.0× | n/a | — |
| Net debt / EBITDA | 0.3× | 2.2× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |